特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
954258

ウイルスベクターおよびプラスミドDNA製造の世界市場(2020年~2027年)

Global Viral Vector and Plasmid DNA Manufacturing Market - 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
ウイルスベクターおよびプラスミドDNA製造の世界市場(2020年~2027年)
出版日: 2020年08月20日
発行: DataM Intelligence
ページ情報: 英文
納期: 即日から翌営業日
担当者のコメント
この一年、大手製薬会社様や診断メーカー様からの幅広いお問い合わせニーズのある、ウイルスベクターおよびプラスミドDNA製造のグローバル市場分析を行った最新調査レポートがDataM Intelligenceよりリリースされました。
  • 全表示
  • 概要
  • 目次
概要

世界のウイルスベクターおよびプラスミドDNA製造市場は、DNAワクチン、遺伝子治療、免疫療法などを開発するためのウイルスベクターおよびプラスミドDNA製造の需要の高まりに牽引されています。高いトランスフェクション効率、効果的な遺伝子送達、安定した遺伝子発現などの利点により、ウイルスベクターとプラスミドDNAの使用が増加しに伴い、ウイルスベクターやプラスミドDNAの有効性や安全性を調べるための臨床研究が増加しています。また、世界市場において北米が市場を独占しています。予測期間中には、遺伝子疾患、がん、感染症などの治療へのウイルスベクター・プラスミドDNAの使用を評価するための臨床試験の増加による市場拡大が見込まれています。先進細胞治療薬の承認が増加していることが市場の成長を促進すると考えられ、遺伝子治療の研究開発活動が活発化しています。食品医薬品局(FDA)による細胞および遺伝子治療の規制支援の改善に向けた取り組みの増加は、ウイルスベクターおよびプラスミドDNA製造の需要を後押しするものと見込まれています。

当レポートは、世界のウイルスベクターおよびプラスミドDNA製造市場について調査しており、市場成長および抑制要因、影響や機会、製品タイプ・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 市場調査手法と範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 製品タイプ別の市場内訳
  • 用途別の市場内訳
  • 地域市場内訳

第4章 市場力学

  • 市場に影響を与える要因
    • 成長要因
    • 抑制要因
    • 影響分析
  • 市場機会

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • 価格分析

第6章 市場分析:製品タイプ別

  • イントロダクション
    • 市場規模分析、および前年比成長分析
    • 市場魅力度指数
  • プラスミドDNA
  • ウイルスベクター
    • レトロウイルスベクター
    • アデノウイルスベクター
    • レンチウイルスベクター
    • アデノ随伴ウイルスベクター
    • その他
  • 非ウイルスベクター

第7章 市場分析:用途別

  • イントロダクション
    • 市場規模分析、および前年比成長分析
    • 市場魅力度指数
  • 遺伝性疾患
  • 感染症
  • その他の病気

第8章 市場分析:地域別

  • イントロダクション
    • 市場規模分析、および前年比成長分析
    • 市場魅力度指数
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東とアフリカ

第9章 競合情勢

  • 競合シナリオ
  • 市場での位置づけ/シェア分析
  • 合併と買収の分析

第10章 企業プロファイル

  • Brammer Bio
  • Cobra Biologics
  • Cell and Gene Therapy Catapult
  • FinVector Vision Therapies
  • Fujifilm Diosynth Biotechnologies(富士フイルム株式会社)
  • MassBiologics
  • SIRION Biotech
  • Merck KGaA Inc.
  • Thermo Fisher Scientific
  • Uniqure NV

第11章 重要考察

第12章 DataMについて

目次

Market Overview

Viral vector is referred as the tool for delivering the genetic material into cells. The modified viral vector is used as the viral vectors in gene therapy. Plasmid DNA is a bacterial smaller, circular and extrachromosomal DNA used in the different molecular genetic research such as gene therapy, gene transfer and recombinant DNA technology due to its self-replication property. A gene of interest is transferred into the target cell for studying the function or expression of a gene. The global viral vector and plasmid DNA manufacturing market valued USD XX million in 2018 and it is expected to grow at a CAGR of XX% to reach USD XX million by 2026.

Market Dynamics:

The market is driven by the increasing demand for the viral vectors and plasmid DNA manufacturing for developing the DNA vaccines, gene therapy, immunotherapy, and others. There is growing usage of the viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is increase in the number of the clinical studies for examining the efficacy and safety of the viral vectors and plasmid DNA.

There is increase in the launch of the contract manufacturing business for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis had launched the contract manufacturing business for plasmid DNA production. The company would establish additional smaller scale reactors (60-300 L, 6-30 L) with feasibility runs and start small volume production service. Genopis is equipped with the right technologies and quality systems.

Several companies are entering into the collaboration with the several organizations for the manufacturing of the viral vectors and plasmid DNA. For instance, in June 2020, Oxford Biomedica plc had entered into the collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization established to provide the UK's first strategic vaccine development and advanced manufacturing capability. This five-year agreement would involve the organizations working collaboratively to enable the manufacture of viral vector-based vaccines, contributing towards a rapid increase in the United Kingdom domestic capacity for this specialized field of vaccine manufacturing. Under the terms of the agreement, VMIC would provide manufacturing equipment for Oxford Biomedica to equip two new GMP manufacturing suites within Oxford Biomedica's new 7,800 m2 commercial manufacturing center, Oxbox, located in Oxford, United Kingdom.

Segment Analysis

The global viral vector and plasmid DNA manufacturing market is segmented based on the product type as the plasmid DNA, viral vector, and non-viral vector. The viral vector segment accounts for the highest market growth due to the increasing penetration of the viral vectors for targeted delivery, efficient transduction, and controlled gene expression. There is increased in the usage of the viral vectors due to their efficiency in delivery gene into the target cells and protecting the new genes from degradation. Different types of the viral vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus and herpes simplex virus are used for transferring the nucleic acids into the genetic makeup of cells. Out of these viral vectors, adenovirus and retrovirus are widely used across the globe as these viral vectors have the integration ability with large transgenes and easy production at high titers.

Several companies are focusing on the expansion of the manufacturing facilities for the viral vectors to meet the increasing demand. For instance, in May 2019, Thermo Fisher Scientific Inc. had opened its new $90 million viral vector contract development and manufacturing organization (CDMO) site in Lexington, MA. The 50,000-square-foot facility would support the development, testing and manufacture of viral vectors essential for advancing gene and cell therapies globally.

Further, the market is also classified based on the application as the cancer, genetic disorder, infectious disease, and other diseases. The cancer segment accounts for the highest market share of XX% in 2019 due to the higher usage of the viral vector, and plasmid DNA for delivering the anticancer genes. Several biotechnology and pharmaceutical companies are examining the viral vectors or plasmid DNA encoding a therapeutic gene, often an immunomodulatory or suicide gene in the various cancer gene therapy trials. Clinical studies have demonstrated that the injection of a plasmid DNA encoding a cytokine gene have a significant antitumor effect. There is increasing research and development activities for the gene therapies and other advanced cell therapies for the treatment of the various cancers. The increase in the approval of the viral vector, and plasmid DNA based therapies shall stimulate the market growth. For instance, the approval of the lentiviral vector-based CAR-T cell therapies for the treatment of Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma.

Geographical Presentation

By region, the global viral vector and plasmid DNA manufacturing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global viral vector and plasmid DNA manufacturing market and expected to grow at the highest CAGR during the forecasted period due to the increasing number of the clinical studies for evaluating the use of the viral vector and plasmid DNA for the treatment of the genetic disorders, cancer, and infectious diseases. The increase in the approval of the advanced cell therapies shall stimulate the market growth. There is growing research and development activities of the gene therapies. Several companies, institutes, associations, and foundations are raising the investment and funding for the development of the gene therapies. The growing initiatives by the Food and Drug Administration (FDA) for improving the regulatory support for the cell and gene therapy shall boost the demand for the viral vector and plasmid DNA manufacturing.

Asia Pacific is expected to witness the positive market growth due to the growing clinical transformation and industrialization of advanced therapies medicinal products including the gene therapy manufacturing. There is presence of the several companies manufacturing the viral vector and plasmid DNA. Contract manufacturers are providing the several services for viral vector and plasmid DNA manufacturing. There is growing adoption of the advanced technologies for manufacturing the viral vector and plasmid DNA.

Competitive Analysis

The global viral vector and plasmid DNA manufacturing market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Uniqure NV are the leading market players with significant market share.

The major players are entering into the collaborations, acquisitions, mergers, and licensing activities for increasing their market presence. For instance, in August 2019, FUJIFILM Corporation had acquired the Biogen (Denmark) Manufacturing ApS, a large-scale biologic manufacturing site located in Hillerød near Copenhagen, Denmark from Biogen. The Hillerød Manufacturing site would be the fourth biopharmaceutical manufacturing site of FUJIFILM Diosynth Biotechnologies, a subsidiary of Fujifilm and a leading Contract Development and Manufacturing Organization (CDMO) with expertise in the development and manufacture of biologics and advanced therapies.

In March 2019, Merck had entered into the non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing. The manufacturing of high-quality plasmid and viral vectors would help in the commercialization of cell and gene therapy. This collaboration would help the company to accelerate the industrialization and commercialization of cell and gene therapy in China. Merck would provide GenScript with comprehensive products, training and consulting services covering process design, facility concept design and quality management system set-up from lab development to large-scale GMP manufacturing.

In December 2017, MilliporeSigma had entered into the commercial supply agreement to manufacture viral vectors for bluebird bio, Inc., of Cambridge, Massachusetts, for its use in potentially transformative gene therapies. Under the terms of agreement, MilliporeSigma would manufacture lentiviral vectors for bluebird bio's drug products developed to treat a variety of rare genetic diseases. This contract builds upon MilliporeSigma's deep experience in producing viral vectors for gene therapy from clinical to commercial scale.

In June 2014, Applied Genetic Technologies Corporation had entered into the collaboration with the Sigma-Aldrich Corporation to provide the gene therapy manufacturing services to companies developing gene-based therapies. Under the terms of the agreement, the two companies will co-market AGTC's proprietary HAVE manufacturing method with SAFC's cGMP manufacturing capabilities. AGTC will assist clients in engineering AAV-based vectors and the associated helper viruses for HAVE-based manufacturing activities. SAFC will manufacture AAV vectors with the HAVE system to either support initial research or in accordance with cGMP requirements to support clinical trial development and eventual commercial production.

Why Purchase the Report?

  • Visualize the composition of the global viral vector and plasmid DNA manufacturing market products in terms of product type and application highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the global viral vector and plasmid DNA manufacturing market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global viral vector and plasmid DNA manufacturing market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • *The global viral vector and plasmid DNA manufacturing market report will provide access to approximately 53 market data tables, 44 figures, and 178 pages

Target Audience

  • Industry Investors/Investment Bankers
  • Suppliers/Buyers
  • Education & Research Institutes
  • Manufacturers
  • Research Professionals
  • Emerging Companies
  • Distributors

Table of Contents

1. Global Viral Vector and Plasmid DNA Manufacturing Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Viral Vector and Plasmid DNA Manufacturing Market - Market Definition and Overview

3. Global Viral Vector and Plasmid DNA Manufacturing Market - Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Global Viral Vector and Plasmid DNA Manufacturing Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Impact Analysis
  • 4.2. Opportunity

5. Global Viral Vector and Plasmid DNA Manufacturing Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis

6. Global Viral Vector and Plasmid DNA Manufacturing Market - By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Plasmid DNA*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  • 6.3. Viral Vector
    • 6.3.1. Retroviral Vectors
    • 6.3.2. Adenoviral Vectors
    • 6.3.3. Lentiviral Vectors
    • 6.3.4. Adeno-associated Viral Vectors
    • 6.3.5. Others
  • 6.4. Non-Viral Vector

7. Global Viral Vector and Plasmid DNA Manufacturing Market - By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, USD Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
  • 7.3. Genetic Disorder
  • 7.4. Infectious Disease
  • 7.5. Other Diseases

8. Global Viral Vector and Plasmid DNA Manufacturing Market - By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. U.K.
      • 8.3.5.3. France
      • 8.3.5.4. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. Australia
      • 8.5.5.5. Rest of Asia Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

9. Global Viral Vector and Plasmid DNA Manufacturing Market Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Market Positioning/Share Analysis
  • 9.3. Mergers and Acquisitions Analysis

10. Global Viral Vector and Plasmid DNA Manufacturing Market Company Profiles

  • 10.1. Brammer Bio*
    • 10.1.1. Company Overview
    • 10.1.2. Form Portfolio and Description
    • 10.1.3. Key Highlights
    • 10.1.4. Financial Overview
  • 10.2. Cobra Biologics
  • 10.3. Cell and Gene Therapy Catapult
  • 10.4. FinVector Vision Therapies
  • 10.5. Fujifilm Diosynth Biotechnologies
  • 10.6. MassBiologics
  • 10.7. SIRION Biotech
  • 10.8. Merck KGaA Inc.
  • 10.9. Thermo Fisher Scientific
  • 10.10. Uniqure NV
  • List is not exhaustive

11. Global Viral Vector and Plasmid DNA Manufacturing Market - Premium Insights

12. Global Viral Vector and Plasmid DNA Manufacturing Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.